Showing results (241-250 of 267) with videos related to

Sort By:
Pageof 27
Research and Practice in Thrombosis and Haemostasis|December 9, 2025
Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETEManuel Monreal, Benjamin Brenner, Covadonga Gómez-Cuervo, et al.
Thrombosis Research|July 22, 2020
Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopeniaRamón Lecumberri, Pedro Ruiz-Artacho, Javier Trujillo-Santos, et al.
The American Journal of Medicine|May 29, 2018
Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous ThromboembolismBenjamin Brenner, Behnood Bikdeli, Inna Tzoran, et al.
European Journal of Internal Medicine|February 11, 2023
Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolismMaria Cristina Vedovati, Michela Giustozzi, Andrés Munoz, et al.
Thrombosis and Haemostasis|May 4, 2021
SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic ThrombocytopeniaIsmail Elalamy, Grigoris Gerotziafas, Sonia Alamowitch, et al.
Thrombosis and Haemostasis|September 16, 2021
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of CancerGiancarlo Agnelli, Andrés Muñoz, Laura Franco, et al.
Research and Practice in Thrombosis and Haemostasis|February 9, 2026
Venous thromboembolism in patients with breast, ovarian, and uterine cancer. A comparative analysis from the Registro Informatizado Enfermedad TromboEmbólica registryOlga Gavín Sebastián, Javier Trujillo-Santos, María Del Carmen Díaz-Pedroche, et al.
The Lancet. Neurology|June 15, 2007
Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort studyGili Kenet, Fenella Kirkham, Thomas Niederstadt, et al.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
Cancer Medicine|February 24, 2024
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximabTali Shafat, Daniel Grupel, Tzvika Porges, et al.
Pageof 27